CLINICAL NEWS
Written in
Featured research from recent issues of Blood
PAPER SPOTLIGHT
Long-Acting Recombinant
Fusion Protein rIX-FP Is
Safe, Effective for Patients
with Hemophilia B
The recombinant fusion
protein linking coagulation factor IX with albumin
(rIX-FP) is a safe and
effective treatment for
patients with hemophilia
B, according to results
from a recent phase III trial
published in Blood. Also,
given its longer circulating
half-life, rIX-FP may be a
more convenient option for
patients, resulting in less
frequent injections.
Current prophylaxis
treatment calls for frequent intravenous (IV)
injections of FIX replacement product, with the
standard half-life of these
products often necessitating IV injections twice
weekly. The need for
frequent injections can put
a burden on both patients
with hemophilia B and
their caregivers and may
affect long